News

AddToAny

Google+ Facebook Twitter Twitter

Kidney transplant rejection biomarker

Scientists have discovered a blood biomarker that predicts kidney transplant rejection with a lead time of about eight months.

This could give doctors an opportunity to intervene and prevent permanent damage.

The results identify a warning signal that something is wrong and suggest an existing medication that could be given to these patients to right the course of their long-term recovery.

Senior author David Rothstein said: “We wanted to find something that would tell us this patient is at risk of rejecting later so that we could change their immunosuppressants up front before the immune system revs up, before scarring and chronic damage is done.”

About a third of patients lose their transplanted kidney within 10 years. At that point, a new transplant isn’t easy. The patient’s immune system is already sensitised to the foreign organ, and it’s harder to find a match.

Rothstein and colleagues from the University of Pittsburgh School of Medicine analysed blood samples taken from 339 patients who received kidney transplants and found a highly predictive biomarker.

Of the patients who were identified as high-risk for rejection based on this new biomarker, 91% rejected the organ within the first year, compared with 10% in the low-risk group. 

The high-risk group was significantly more likely to lose their transplanted kidneys five years post surgery.  

bit.ly/3qaEZTl

Related Articles

web_blood-testing_credit_istock-1384651794.png

SPONSORED: The power of automated gel-based ID-cards in routine immunohematology workflows

Immuno-haematology assays are pivotal to the carrying out of blood grouping, antibody screening and transfusions, and represent a critically time-dependent stage in the patient management pathway.

Technician holding a blood sample ready for testing with other human medical samples in the background.-Image credit - Science-Photo-Library-f0243823

Machine learning tool to detect cancer via liquid biopsy

US researchers have developed and tested an innovative machine-learning approach that could one day enable the earlier detection of cancer in patients by using smaller blood draws.

multiple myelomatosis-CREDIT-Science Photo Library-m132099

IBMS research grants

We look at the work of Dr Mosavar Farahani who received an IBMS Research Grant in 2023 to help fund her work on disease progression and skeletal complications in multiple myeloma.

Jaxon Moran and Emily Jones

My Lab: Flow cytometry laboratory

Jaxon Moran and Emily Jones give a guided tour of the Flow Cytometry Laboratory at Newcastle upon Tyne Hospitals NHS Foundation Trust.

Top